. 2022 Dec 1;19(12):2053–2061. doi: 10.1513/AnnalsATS.202203-275OC

Table 2.

Unadjusted rates of adverse events among patients with early stage non-small cell lung cancer treated with stereotactic body radiation therapy versus limited resection

Adverse Event	30 d Post Treatment					90 d Post Treatment
	SBRT	Grade III/IV	Surgery	Grade III/IV	P Value^*	SBRT	Grade III/IV	Surgery	Grade III/IV	P Value^*
	No. (%)^†	No. (%)^‡	No. (%)^†	No. (%)^‡	P Value^*	No. (%)^†	No. (%)^‡	No. (%)^†	No. (%)^‡	P Value^*
At least 1 AE	42 (25.6)	6 (14.2)	26 (29.6)	3 (11.5)	0.50	56 (34.2)	6 (10.7)	30 (34.1)	3 (10.0)	0.99
Constitutional	29 (17.7)	0 (0.0)	7 (8.0)	0 (0.0)	0.04	35 (21.3)	0 (0.0)	8 (9.1)	0 (0.0)	0.01
Respiratory	15 (41.7)	2 (13.3)	21 (58.3)	1 (4.8)	<0.01	21 (46.7)	3 (14.3)	24 (53.3)	1 (4.1)	<0.01
Infectious	1 (0.6)	0 (0.0)	7 (8.0)	2 (28.5)	<0.01	7 (4.3)	2 (28.5)	7 (8.0)	2 (28.5)	0.25
Cardiovascular	1 (0.6)	1 (100.0)	2 (2.3)	0 (0.0)	0.28	1 (0.6)	1 (100.0)	4 (4.6)	0 (0.0)	0.05
Cutaneous	3 (1.8)	1 (33.3)	0 (0.0)	0 (0.0)	0.55	4 (2.4)	1 (25.0)	0 (0.0)	0 (0.0)	0.30
Musculoskeletal	4 (2.4)	1 (25.0)	2 (2.3)	0 (0.0)	0.99	5 (3.1)	1 (20.0)	2 (2.3)	0 (0.0)	0.99
Gastrointestinal	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0.99	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0.99
Neurological	1 (0.6)	1 (100.0)	0 (0.0)	0 (0.0)	0.99	1 (0.6)	1 (100.0)	0 (0.0)	0 (0.0)	0.99
Hematological	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)	0.35	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)	0.35

Definition of abbreviations: AE = adverse event; SBRT = stereotactic body radiation therapy.

P value compares the statistical significance for overall (i.e., all grades) AEs between SBRT vs. surgery.

^{^†}

Indicates the percentage of participants in the treatment group that experienced AEs of any level of severity.

^{^‡}

Indicates percentage of the total AEs that were grade III or IV.